These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14698295)

  • 1. Evolution of aldolase antibodies in vitro: correlation of catalytic activity and reaction-based selection.
    Tanaka F; Fuller R; Shim H; Lerner RA; Barbas CF
    J Mol Biol; 2004 Jan; 335(4):1007-18. PubMed ID: 14698295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
    Rader C; Turner JM; Heine A; Shabat D; Sinha SC; Wilson IA; Lerner RA; Barbas CF
    J Mol Biol; 2003 Sep; 332(4):889-99. PubMed ID: 12972259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of small designer aldolase enzymes: catalytic activity, folding, and substrate specificity.
    Tanaka F; Fuller R; Barbas CF
    Biochemistry; 2005 May; 44(20):7583-92. PubMed ID: 15896002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-catalyzed benzoin oxidation as a mechanistic probe for nucleophilic catalysis by an active site lysine.
    Sklute G; Oizerowich R; Shulman H; Keinan E
    Chemistry; 2004 May; 10(9):2159-65. PubMed ID: 15112204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple catalytic aldolase antibodies suitable for chemical programming.
    Goswami RK; Huang ZZ; Forsyth JS; Felding-Habermann B; Sinha SC
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3821-4. PubMed ID: 19428247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune versus natural selection: antibody aldolases with enzymic rates but broader scope.
    Barbas CF; Heine A; Zhong G; Hoffmann T; Gramatikova S; Björnestedt R; List B; Anderson J; Stura EA; Wilson IA; Lerner RA
    Science; 1997 Dec; 278(5346):2085-92. PubMed ID: 9405338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring substrate binding and discrimination in fructose1, 6-bisphosphate and tagatose 1,6-bisphosphate aldolases.
    Zgiby SM; Thomson GJ; Qamar S; Berry A
    Eur J Biochem; 2000 Mar; 267(6):1858-68. PubMed ID: 10712619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The origin of enantioselectivity in aldolase antibodies: crystal structure, site-directed mutagenesis, and computational analysis.
    Zhu X; Tanaka F; Hu Y; Heine A; Fuller R; Zhong G; Olson AJ; Lerner RA; Barbas CF; Wilson IA
    J Mol Biol; 2004 Nov; 343(5):1269-80. PubMed ID: 15491612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldol sensors for the rapid generation of tunable fluorescence by antibody catalysis.
    List B; Barbas CF; Lerner RA
    Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15351-5. PubMed ID: 9860972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly efficient antibody-catalyzed deuteration of carbonyl compounds.
    Shulman A; Sitry D; Shulman H; Keinan E
    Chemistry; 2002 Jan; 8(1):229-39. PubMed ID: 11822454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enantioselective aldol cyclodehydrations catalyzed by antibody 38C2.
    List B; Lerner RA; Barbas CF
    Org Lett; 1999 Jul; 1(1):59-61. PubMed ID: 10822533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes.
    Wagner J; Lerner RA; Barbas CF
    Science; 1995 Dec; 270(5243):1797-800. PubMed ID: 8525368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amperometric assay for aldolase activity: antibody-catalyzed ferrocenylamine formation.
    Sagi A; Rishpon J; Shabat D
    Anal Chem; 2006 Mar; 78(5):1459-61. PubMed ID: 16503594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational elucidation and validation of the three-dimensional structure of humanized aldolase catalytic antibody 38C2.
    Jayakody RS; Jasin Arachchige LI; Japahuge A
    J Biomol Struct Dyn; 2021 Apr; 39(7):2463-2477. PubMed ID: 32242499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial aldolases from peptide dendrimer combinatorial libraries.
    Kofoed J; Darbre T; Reymond JL
    Org Biomol Chem; 2006 Sep; 4(17):3268-81. PubMed ID: 17036115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Snapshots of catalysis: the structure of fructose-1,6-(bis)phosphate aldolase covalently bound to the substrate dihydroxyacetone phosphate.
    Choi KH; Shi J; Hopkins CE; Tolan DR; Allen KN
    Biochemistry; 2001 Nov; 40(46):13868-75. PubMed ID: 11705376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.
    Sinha SC; Das S; Li LS; Lerner RA; Barbas CF
    Nat Protoc; 2007; 2(2):449-56. PubMed ID: 17406606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using the process of reactive immunization to induce catalytic antibodies with complex mechanisms: aldolases.
    Lerner RA; Barbas CF
    Acta Chem Scand (Cph); 1996 Aug; 50(8):672-8. PubMed ID: 8756355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic screening for catalytic promiscuity in 4-oxalocrotonate tautomerase: enamine formation and aldolase activity.
    Zandvoort E; Baas BJ; Quax WJ; Poelarends GJ
    Chembiochem; 2011 Mar; 12(4):602-9. PubMed ID: 21290551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.
    Popkov M; Rader C; Gonzalez B; Sinha SC; Barbas CF
    Int J Cancer; 2006 Sep; 119(5):1194-207. PubMed ID: 16570283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.